Study S002796

Investigation of Pharmacokinetic Properties, Safety and Tolerability of Single Subcutaneous Doses of NNC0174-0833 in Male Japanese and Caucasian Subjects Being Normal Weight, Overweight or With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT03787225
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 66
Start: 2019-01-07
Primary completion: 2019-06-04
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight
Interventions: DRUG:NNC0174-0833; DRUG:Placebo (NNC0174-0833)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1219-7303

Registered primary outcomes

AUC0-∞,AM833: the area under the NNC0174-0833 plasma concentration-time curve from time 0 to infinity after single dose [From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.